Agomab draws $100M for fibrosis pipeline, adding to drumbeat of nine-figure Series C rounds
Agomab Therapeutics has reeled in $100 million that is set to bankroll the Belgian biotech through a Phase II study in a subset of Crohn’s disease and Phase 1 trials of other investigational treatments for fibrotic conditions.
The Series C, which was disclosed Tuesday, could give Agomab the option to explore an eventual Nasdaq listing or the potential to partner on one or multiple drug candidates, CEO Tim Knotnerus told Endpoints News. Fidelity Management & Research Company led the round, which also included EQT Life Sciences, Canaan, KKR’s Dawn Biopharma and existing investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.